Semi Xilia MP 2mg/500mg/7.5mg Tablet SR
Marketer
Emcure Pharmaceuticals Ltd
Salt Composition
Glimepiride (2mg) + Metformin (500mg) + Pioglitazone (7.5mg)
Overview Semi Xilia MP 2mg/500mg/7.5mg Tablet SR
Xylo-Trio 2mg/500mg/7.5mg Extended-Release Tablets combine medications to manage blood glucose. This therapy, used alongside diet and exercise, improves glycemic control in adult patients with type 2 diabetes. It enhances insulin effectiveness, reducing blood sugar. Dosage and frequency of Xylo-Trio 2mg/500mg/7.5mg Extended-Release Tablets should strictly follow your physician's instructions. Administer with food to minimize gastrointestinal discomfort. For missed doses, take immediately unless the next dose is imminent; in that case, omit the missed dose and resume the regular schedule. Never double the dose. Overdosage can result in hypoglycemia. Concomitant use with other antidiabetic agents, alcohol consumption, or meal skipping may increase the risk of hypoglycemia. Regular blood glucose monitoring is vital. Common adverse effects include nausea, diarrhea, abdominal pain, headache, bone fractures, and respiratory infections. Prior to initiating treatment, disclose any kidney, liver, or heart conditions to your doctor. Pregnant or lactating individuals should consult their physician. Renal function tests are typically performed before treatment commences. Limit alcohol consumption to mitigate potential side effects.
Uses of Semi Xilia MP 2mg/500mg/7.5mg Tablet SR
Managing type 2 diabetes
Major Benefits of Semi Xilia MP 2mg/500mg/7.5mg Tablet SR:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Consume Semi Xilia MP 2 mg/500 mg/7.5 mg Extended-Release tablets with food.
Common Side effects of Semi Xilia MP 2mg/500mg/7.5mg Tablet SR:
- Hypoglycemia (low blood glucose level)
- Headache
- Nausea
- Diarrhea
- Dizziness
- Vomiting
- Anemia (low number of red blood cells)
- Weakness
- Sinus infection
How to use Semi Xilia MP 2mg/500mg/7.5mg Tablet SR:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Semi Xilia MP 2 mg/500 mg/7.5 mg sustained-release tablet should be administered with a meal.
How Semi Xilia MP 2mg/500mg/7.5mg Tablet SR works:
Semi Xilia MP, a sustained-release tablet containing 2 mg glimepiride, 500 mg metformin, and 7.5 mg pioglitazone, offers triple-action antidiabetic therapy. This combination leverages distinct mechanisms to optimize blood glucose management when monotherapy or dual therapy proves insufficient. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion, thus reducing blood glucose. Metformin, a biguanide, acts by decreasing hepatic glucose production, retarding intestinal glucose absorption, and enhancing insulin sensitivity. Pioglitazone, a thiazolidinedione, further improves insulin responsiveness.
SAFETY ADVICE
AlcoholUNSAFE
Combining Semi Xilia MP 2 mg/500 mg/7.5 mg SR tablets with alcohol is unsafe.
PregnancyCONSULT YOUR DOCTOR
The use of Semi Xilia MP 2 mg/500 mg/7.5 mg Tablet SR during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the potential benefits against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release tablet formulation of Semi Xilia MP (2 mg/500 mg/7.5 mg) is likely not safe for breastfeeding mothers. Available human data indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyCAUTION
Exercise caution when administering Semi Xilia MP 2 mg/500 mg/7.5 mg SR tablets to individuals with impaired kidney function; dosage modification may be necessary. Consult a physician for guidance. Avoid using Semi Xilia MP 2 mg/500 mg/7.5 mg SR tablets in patients exhibiting severe kidney disease. Close monitoring of renal function is recommended during treatment.
LiverCAUTION
Patients with hepatic impairment should use Semi Xilia MP 2 mg/500 mg/7.5 mg SR tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. Semi Xilia MP 2 mg/500 mg/7.5 mg SR tablets are contraindicated in individuals with severe liver disease.
What if you forget to take Semi Xilia MP 2mg/500mg/7.5mg Tablet SR :
Should you forget to take your Semi Xilia MP 2 mg/500 mg/7.5 mg Tablet SR, administer it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Semi Xilia MP 2mg/500mg/7.5mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently